Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash to Debt 5.11
CNDO's Cash to Debt is ranked higher than
67% of the 1275 Companies
in the Global Biotechnology industry.

( Industry Median: 69.96 vs. CNDO: 5.11 )
CNDO' s 10-Year Cash to Debt Range
Min: 2.76   Max: No Debt
Current: 5.11

F-Score: 3
Z-Score: 1.76
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
ROE (%) -34.30
CNDO's ROE (%) is ranked higher than
74% of the 1159 Companies
in the Global Biotechnology industry.

( Industry Median: -33.71 vs. CNDO: -34.30 )
CNDO' s 10-Year ROE (%) Range
Min: -380.1   Max: -71.93
Current: -34.3

-380.1
-71.93
ROA (%) -27.49
CNDO's ROA (%) is ranked higher than
74% of the 1279 Companies
in the Global Biotechnology industry.

( Industry Median: -27.24 vs. CNDO: -27.49 )
CNDO' s 10-Year ROA (%) Range
Min: -311.1   Max: -52.49
Current: -27.49

-311.1
-52.49
ROC (Joel Greenblatt) (%) -11577.13
CNDO's ROC (Joel Greenblatt) (%) is ranked higher than
54% of the 1249 Companies
in the Global Biotechnology industry.

( Industry Median: -347.70 vs. CNDO: -11577.13 )
CNDO' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -106572.55   Max: -14369.48
Current: -11577.13

-106572.55
-14369.48
» CNDO's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

CNDO Guru Trades in Q1 2014

Jim Simons 392,412 sh (+1018.81%)
Chuck Royce 530,000 sh (unchged)
Paul Singer 3,731,279 sh (unchged)
Paul Tudor Jones Sold Out
» More
Q2 2014

CNDO Guru Trades in Q2 2014

George Soros 29,279 sh (New)
Jim Simons 523,900 sh (+33.51%)
Paul Singer 3,731,279 sh (unchged)
Chuck Royce 530,000 sh (unchged)
» More
Q3 2014

CNDO Guru Trades in Q3 2014

Paul Singer 3,731,279 sh (unchged)
Chuck Royce 530,000 sh (unchged)
George Soros Sold Out
Jim Simons 187,719 sh (-64.17%)
» More
Q4 2014

CNDO Guru Trades in Q4 2014

Paul Singer 3,731,279 sh (unchged)
Jim Simons Sold Out
Chuck Royce 467,400 sh (-11.81%)
» More
» Details

Insider Trades

Latest Guru Trades with CNDO

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
George Soros 2014-09-30 Sold Out $1.48 - $2.16 $ 3.2382%0
George Soros 2014-06-30 New Buy$1.55 - $2.02 $ 3.2384%29279
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 1.79
CNDO's P/B is ranked higher than
94% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 6.25 vs. CNDO: 1.79 )
CNDO' s 10-Year P/B Range
Min: 0   Max: 61.8
Current: 1.79

0
61.8
EV-to-EBIT -2.16
CNDO's EV-to-EBIT is ranked higher than
77% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. CNDO: -2.16 )
CNDO' s 10-Year EV-to-EBIT Range
Min: 0   Max: 0
Current: -2.16

Current Ratio 20.26
CNDO's Current Ratio is ranked higher than
95% of the 1267 Companies
in the Global Biotechnology industry.

( Industry Median: 4.61 vs. CNDO: 20.26 )
CNDO' s 10-Year Current Ratio Range
Min: 4.7   Max: 22.25
Current: 20.26

4.7
22.25
Quick Ratio 20.26
CNDO's Quick Ratio is ranked higher than
95% of the 1267 Companies
in the Global Biotechnology industry.

( Industry Median: 4.41 vs. CNDO: 20.26 )
CNDO' s 10-Year Quick Ratio Range
Min: 4.7   Max: 22.25
Current: 20.26

4.7
22.25

Valuation & Return

vs
industry
vs
history
Price/Net Cash 2.34
CNDO's Price/Net Cash is ranked higher than
97% of the 1357 Companies
in the Global Biotechnology industry.

( Industry Median: 56.66 vs. CNDO: 2.34 )
CNDO' s 10-Year Price/Net Cash Range
Min: 1.3   Max: 11.92
Current: 2.34

1.3
11.92
Price/Net Current Asset Value 2.34
CNDO's Price/Net Current Asset Value is ranked higher than
97% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 36.79 vs. CNDO: 2.34 )
CNDO' s 10-Year Price/Net Current Asset Value Range
Min: 1.3   Max: 11.92
Current: 2.34

1.3
11.92
Price/Tangible Book 1.79
CNDO's Price/Tangible Book is ranked higher than
95% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 9.29 vs. CNDO: 1.79 )
CNDO' s 10-Year Price/Tangible Book Range
Min: 1.06   Max: 11.75
Current: 1.79

1.06
11.75
Earnings Yield (Greenblatt) -46.30
CNDO's Earnings Yield (Greenblatt) is ranked lower than
51% of the 1255 Companies
in the Global Biotechnology industry.

( Industry Median: -5.40 vs. CNDO: -46.30 )
CNDO' s 10-Year Earnings Yield (Greenblatt) Range
Min: -410.2   Max: 2627.7
Current: -46.3

-410.2
2627.7

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Traded in other countries:CNB.Germany,
Coronado Biosciences Inc was incorporated on June 28, 2006. It is a biopharmaceutical company focused on novel immunotherapy biologic agents for autoimmune diseases and cancer. Its two main product candidates in clinical development are: TSO and CNDO-109. TSO, or CNDO-201, is a biologic comprising Trichuris suis ova, the microscopic eggs of the porcine whipworm. TSO is a biologic product candidate for the treatment of autoimmune diseases. CNDO-109 is a lysate that is disrupted CTV-1 cells, cell membrane fragments, cell proteins and other cellular components that activates donor Natural Killer cells. CTV-1 is a leukemic cell line re-classified as a T-cell acute lymphocytic leukemia, or ALL. The Company faces competition from many different sources, including commercial pharmaceutical and biotechnology enterprises, academic institutions, government agencies, and private and public research institutions. Government authorities in the United States, at the federal, state and local level, and other countries regulate, among other things, the research, development, testing, manufacture, quality control, approval, labeling, packaging, storage, record-keeping, promotion, advertising, distribution, post-approval monitoring and reporting, marketing and export and import of products.
» More Articles for CNDO

Headlines

Articles On GuruFocus.com
Weekly CFO Buys Highlight Jul 28 2013 
Weekly CFO Buys Highlight Jul 21 2013 
Weekly CFO Buys Highlight Jun 11 2013 
Weekly CEO Buys Highlight: CNDO Jan 21 2013 
Coronado Biosciences New CEO Makes First Buy of the Year, Worth $114K Jan 16 2013 
Weekly CEO Buys Highlight: SXL, JBSS, GNMK, CNDO, DCO Jun 30 2012 
Weekly CEO Buys Highlight: SXL, JBSS, GNMK, CNDO, DCO Jun 30 2012 


More From Other Websites
Nasdaq stocks posting largest volume increases Mar 04 2015
Coronado Biosciences Forms New Subsidiary, Checkpoint Therapeutics, to Develop Novel Immuno-Oncology... Mar 04 2015
TG Therapeutics Enters Into a Global Collaboration With Checkpoint Therapeutics to Develop and... Mar 04 2015
Coronado Biosciences Forms New Subsidiary, Checkpoint Therapeutics, to Develop Novel Immuno-Oncology... Mar 04 2015
TG Therapeutics Enters Into a Global Collaboration With Checkpoint Therapeutics to Develop and... Mar 04 2015
Coronado Biosciences Closes $10 Million Private Placement Financing Mar 03 2015
8:35 am Coronado Biosciences has closed a private placement of a promissory note for $10 mln Mar 03 2015
Coronado Biosciences Closes $10 Million Private Placement Financing Mar 03 2015
Coronado Biosciences (CNDO) Jumps: Stock Rises 10.7% - Tale of the Tape Feb 26 2015
Coronado Biosciences In-Licenses Revogenex's Pain Drug - Analyst Blog Feb 19 2015
Coronado Biosciences In-Licenses IV Tramadol, a Phase III Ready Asset, From Revogenex Ireland Ltd. Feb 18 2015
Coronado Biosciences In-Licenses IV Tramadol, a Phase III Ready Asset, From Revogenex Ireland Ltd. Feb 18 2015
Coronado Biosciences (CNDO) Looks Good: Stock Up 7.4% - Tale of the Tape Jan 19 2015
Coronado Biosciences Reports on Separation of CB Pharma Acquisition Corp. Securities Jan 06 2015
Coronado Biosciences Reports on Separation of CB Pharma Acquisition Corp. Securities Jan 06 2015
Coronado Biosciences Announces Exercise of Portion of Over-Allotment Option in Conjunction With CB... Dec 29 2014
Coronado Biosciences Announces Exercise of Portion of Over-Allotment Option in Conjunction With CB... Dec 29 2014
Coronado Biosciences Announces Closing of Initial Public Offering of CB Pharma Acquisition Corp. Dec 18 2014
Coronado Biosciences Announces Closing of Initial Public Offering of CB Pharma Acquisition Corp. Dec 18 2014
Coronado Biosciences Announces Pricing of Initial Public Offering of CB Pharma Acquisition Corp. Dec 15 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK